TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Chiron Pharmasynth AS
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
2,060
|
2,031
|
1,397 |
| Financial expenses |
0
|
27
|
12 |
| Earnings before taxes |
-22
|
451
|
180 |
| Total assets |
2,698
|
2,930
|
2,703 |
| Current assets |
2,698
|
2,930
|
2,703 |
| Current liabilities |
1,106
|
1,229
|
1,034 |
| Equity capital |
1,592
|
1,701
|
1,670 |
| - share capital |
150
|
158
|
169 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
59.0%
|
58.1%
|
61.8% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
-1.1%
|
22.2%
|
12.9% |
| Return on assets (ROA) |
-0.8%
|
16.3%
|
7.1% |
| Current ratio |
243.9%
|
238.4%
|
261.4% |
| Return on equity (ROE) |
-1.4%
|
26.5%
|
10.8% |
| Change turnover |
133
|
722
|
512 |
| Change turnover % |
7%
|
55%
|
58% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.